Skip to contentI
IGC Pharma, Inc.
I
IGCIGC Pharma, Inc. Q1 2026 · 10-Q
Revenue$317.00K$317.00K−3.9% vs Q1 2025 Net Income-$2.40M-$2.40MN/M vs Q1 2025 EPS Diluted-$0.02-$0.02N/M vs Q1 2025 Gross Profit$55,000−64.3% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
IGC Pharma, Inc. · CIK 1326205 · Engraved from SEC EDGAR
Operating Cash Flow-$1,223,000N/M Free Cash Flowderived-$1,224,000N/M Margins · derivedGross margin17.4%−29.3 pt vs Q1 2025
Operating margin-775.4%−347.2 pt vs Q1 2025
Net margin-757.7%−394.7 pt vs Q1 2025
ended Mar 31, 2026 · filed May 15, 2026 · 45 d after period end